An Integrated clinical pathway for diagnosis, treatment and care of rare diseases: model, operating procedures, and results of the project TRANSLATE-NAMSE funded by the German Federal Joint Committee.
Case management
Clinical pathway
Diagnostic odyssey
Evidence-based medicine
Rare diseases
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
12 11 2021
12 11 2021
Historique:
received:
01
04
2021
accepted:
17
10
2021
entrez:
13
11
2021
pubmed:
14
11
2021
medline:
12
3
2022
Statut:
epublish
Résumé
Diagnosis, treatment, and care of patients with rare diseases require multidisciplinary cooperation between medical and paramedical specialities and with patients and families. Innovative genetic diagnostics, whole exome and whole genome sequencing (WES, WGS) has enlarged the diagnostic toolkit but also increased the complexity of the endeavour. Structured multidisciplinary clinical pathways (CPW) can guide diagnosis, treatment, and care of patients with rare diseases, link scientific evidence to clinical practice and optimise clinical outcomes whilst maximising clinical efficiency. In contrast to the common approach of appending disease-specific CPWs to disease-specific guidelines, we suggest a generic CPW manoeuvring the patient along the way of finding the correct diagnosis by applying the best diagnostic strategy into an appropriate system of treatment and care. Available guidelines can be integrated into the generic CPW in the course of its application. The approach also applies to situations where a diagnosis remains unsolved. The backbone of the generic CPW is a set of multidisciplinary structured case conferences projecting and evaluating diagnostic and/or therapeutic steps, enforcing to integrate best scientific evidence with clinical experience. The generic CPW is stated as a flowchart and a checklist which can be used to record and document parsimoniously the structure, process and results of a patient's pathway, but also as a data model for research. It was applied in a multicentre setting with 587 cases each with a presumptive diagnosis of a rare disease. In 369 cases (62.8%) a diagnosis could be confirmed, and multidisciplinary treatment and/or care was initiated. The median process time from first contact until confirmation of diagnosis by WES was 109 days and much shorter than diagnostic delays reported in the literature. Application of the CPW is illustrated by two case reports. Our model is a tool to change the diagnostic odyssey into an organised and trackable route. It can also be used to inform patients and families about the stages of their individual route, to update health care providers only partially involved or attending specialised treatment and care, like the patient's or family's primary physician, and finally to train novices in the field.
Sections du résumé
BACKGROUND
Diagnosis, treatment, and care of patients with rare diseases require multidisciplinary cooperation between medical and paramedical specialities and with patients and families. Innovative genetic diagnostics, whole exome and whole genome sequencing (WES, WGS) has enlarged the diagnostic toolkit but also increased the complexity of the endeavour. Structured multidisciplinary clinical pathways (CPW) can guide diagnosis, treatment, and care of patients with rare diseases, link scientific evidence to clinical practice and optimise clinical outcomes whilst maximising clinical efficiency.
RESULTS
In contrast to the common approach of appending disease-specific CPWs to disease-specific guidelines, we suggest a generic CPW manoeuvring the patient along the way of finding the correct diagnosis by applying the best diagnostic strategy into an appropriate system of treatment and care. Available guidelines can be integrated into the generic CPW in the course of its application. The approach also applies to situations where a diagnosis remains unsolved. The backbone of the generic CPW is a set of multidisciplinary structured case conferences projecting and evaluating diagnostic and/or therapeutic steps, enforcing to integrate best scientific evidence with clinical experience. The generic CPW is stated as a flowchart and a checklist which can be used to record and document parsimoniously the structure, process and results of a patient's pathway, but also as a data model for research. It was applied in a multicentre setting with 587 cases each with a presumptive diagnosis of a rare disease. In 369 cases (62.8%) a diagnosis could be confirmed, and multidisciplinary treatment and/or care was initiated. The median process time from first contact until confirmation of diagnosis by WES was 109 days and much shorter than diagnostic delays reported in the literature. Application of the CPW is illustrated by two case reports.
CONCLUSIONS
Our model is a tool to change the diagnostic odyssey into an organised and trackable route. It can also be used to inform patients and families about the stages of their individual route, to update health care providers only partially involved or attending specialised treatment and care, like the patient's or family's primary physician, and finally to train novices in the field.
Identifiants
pubmed: 34772435
doi: 10.1186/s13023-021-02092-w
pii: 10.1186/s13023-021-02092-w
pmc: PMC8588640
doi:
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
474Informations de copyright
© 2021. The Author(s).
Références
JAMA Pediatr. 2020 Sep 1;174(9):821-822
pubmed: 32597967
Arch Dis Child. 1996 Aug;75(2):166-8
pubmed: 8869204
J Genet Couns. 2015 Apr;24(2):325-35
pubmed: 25277096
Orphanet J Rare Dis. 2013 Oct 17;8:167
pubmed: 24135440
Cochrane Database Syst Rev. 2010 Mar 17;(3):CD006632
pubmed: 20238347
Orphanet J Rare Dis. 2011 Jun 20;6:44
pubmed: 21689452
Clin Genet. 2016 Mar;89(3):275-84
pubmed: 26283276
PLoS One. 2019 Oct 31;14(10):e0224286
pubmed: 31671116
Lancet. 2017 Jul 22;390(10092):415-423
pubmed: 28215660
Pediatrics. 2006 Aug;118(2):e488-500
pubmed: 16882788
J Inherit Metab Dis. 2012 Jul;35(4):613-25
pubmed: 22544437
Orphanet J Rare Dis. 2018 Nov 12;13(1):202
pubmed: 30419920
Horm Res Paediatr. 2012;77(3):195-9
pubmed: 22508345
Am J Med Genet A. 2019 Jun;179(6):885-892
pubmed: 30883013
PLoS One. 2017 Feb 24;12(2):e0172532
pubmed: 28234950
Qual Manag Health Care. 1992 Fall;1(1):45-54
pubmed: 10131646
BMJ. 1998 Jan 10;316(7125):133-7
pubmed: 9462322
J Clin Endocrinol Metab. 2007 Jul;92(7):2581-9
pubmed: 17456574
J Clin Endocrinol Metab. 2000 Feb;85(2):658-65
pubmed: 10690872
J Clin Endocrinol Metab. 2018 Nov 1;103(11):4043-4088
pubmed: 30272171
J Mother Child. 2020 Oct 02;24(2):65-72
pubmed: 33179604
Orphanet J Rare Dis. 2013 Feb 25;8:37
pubmed: 23442887
Eur J Pediatr. 2002 Jan;161(1):49-59
pubmed: 11808880
Am J Hum Genet. 2017 Feb 2;100(2):352-363
pubmed: 28132691
Horm Res Paediatr. 2014;81(2):80-103
pubmed: 24662106